| Study Details | This is a Phase 3, open-label, randomized, active-controlled, multicenter study to evaluate the safety and efficacy of ALXN1210 versus eculizumab administered by intravenous (IV) infusion to adult patients with PNH who are naïve to complement inhibitor treatment. |
| Protocol Number | ALXN1210-PNH-301 |
| Phase | III |
| Therapeutic Area | Haematology |
| Subject Types | With Medical Condition |
| Indication | Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Principal Investigator | Dr Yap Eng Soo |
| Investigator Product / Device | ALXN1210 |
| Sponsor | Alexion Pharmaceuticals, Inc |